---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000044"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:45:03.136407+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Serina presents POZ-lipid LNP data showing no immune response in rats, solving PEG antibody issue

## Summary
- POZ-lipid did not trigger IgM or IgG response after repeat dosing in rats in a vaccine format.
- PEG-lipid standard elicited a strong, boosted antibody response under same conditions.
- Anti-PEG antibodies linked to anaphylaxis in mRNA vaccines; POZ-lipid offers immune-silent alternative.
- Data presented at 4th LNP Formulation & Process Development Summit on April 15, 2025.
- Discovery could enable safer LNP formulations for gene therapy and RNA medicines.

## SEC filing metadata
- accession: 0001708599-25-000044
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000044/0001708599-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000044/ser-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000044
- JSON: https://secwatch.observer/filing/0001708599-25-000044.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.